Protein may predict disease progression
Posted on: Friday, 30 January 2009, 22:51 CST
Italian researchers have found blood or urine levels of a protein may predict kidney disease progression.
The study, published in the Clinical Journal of the American Society Nephrology, suggests a small protein released from the kidney's injured tubular cells -- called Neutrophil Gelatinase-Associated Lipocalin -- could help identify patients in need of more aggressive care because their chronic kidney disease is likely to advances to a more serious form.
The investigators evaluated the blood and urine levels of Neutrophil Gelatinase-Associated Lipocalin in 96 patients with non-terminal chronic kidney disease. By the end of the year-and-a-half study, 31 patients experienced significant progression of their disease -- in some cases developing end-stage renal disease.
The researchers noted that at the start of the study, the patients who developed advanced disease had had higher Neutrophil Gelatinase-Associated Lipocalin levels than patients whose disease did not progress. Both urinary Neutrophil Gelatinase-Associated Lipocalin and blood Neutrophil Gelatinase-Associated Lipocalin levels predicted worsening of chronic kidney disease.
Our study offers a great new tool for prevention of renal failure progression,
study leader Dr. Michele Buemi of the University of Messina in Italy said in a statement. The results are particularly important today as chronic kidney disease has become a severe public health problem and incidence rates continue to rise.
Source: United Press International
Related Articles
- Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
- New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP
- Kidney Disease Increases the Risk of Stroke in Patients With the Most Common Type of Heart Arrhythmia, According to Kaiser Permanente Study
- GlobeImmune Announces Presentation of Results From a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients With Chronic Hepatitis C Infection
- XTL Announces the Completion of Phase I Study With XTL-6865 in Patients With Chronic Hepatitis C
- Advocacy for Patients With Chronic Illness, Inc. Releases Case Study
- Disease Management Association Of America (DMAA) and J.D. Power And Associates Collaborate on Patient Satisfaction Effort
- Naryx Pharma, Inc. Announces Significant Results From Its Phase II Study of SPRC-AB01 in Patients With Chronic Rhinosinusitis
- Discovery May Prevent Life-threatening Wasting Disease in Patients with Chronic Kidney Disease
- Benephit Infusion System To Be Studied in Patients With Chronic Kidney Disease Undergoing Cardiovascular Procedures
User Comments (0)

RSS Feeds